Clinical Trials Logo

Clinical Trial Summary

To investigate the efficacy and safety of a 4-week treatment of 5 mg/day or 10 mg/day of E3810 (Pariet (Rabeprazole Sodium)) in patients with non-erosive gastroesophageal reflux disease in a multicenter, randomized, double-blind, comparative study.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00165646
Study type Interventional
Source Eisai Inc.
Contact
Status Completed
Phase Phase 3
Start date September 2004
Completion date October 2005

See also
  Status Clinical Trial Phase
Completed NCT02954848 - Phase 3 Study of TAK-438 10 mg in the Treatment of Non-Erosive Gastroesophageal Reflux Disease (NERD) Phase 3
Completed NCT00165672 - A Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease Phase 3
Completed NCT01047800 - Functional Gastrointestinal Disorder Screening Program - A Randomized Controlled Trial N/A
Recruiting NCT03811080 - Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Non Erosive Reflux Disease Phase 3
Completed NCT01474369 - Efficacy of TAK-438 Compared to Placebo in the Treatment of Non-Erosive Gastroesophageal Reflux Disease Phase 3